| 2010 |
●January, launch the agency business |
| |
|
| 2009 |
●February, construct native antigen R&D platform |
| |
●March, construct sheep polyclonal antibody R&D platform |
| |
●April, launch HRP-II monoclonal antibody |
| |
●May, construct chemiluminescense screening platform |
| |
●June, launch the global leading Heterophilic Immunoglobulin Elimination Reagent (HIER) |
| |
●December, launch Tag DNA polymerase |
| |
●At the end of december, the employee extended to 57 |
| |
|
| 2008 |
●January, launch the leading core material for Tp(Double-antigen Sandwiched) |
| |
●February, successfully develop the global leading anti-clenbuterol monoclona antibody |
| |
●April, construct rabbit polyclonal antibody R&D platform |
| |
●June, obtained SGS ISO9001: 2000 Quality Management System Certification |
| |
●July, attended AACC exhibition as exhibitor |
| |
●September, Get the champion of the “Vature star” in Shenzhen Nanshan District and interviewed by CCTV |
| |
●October, interviewed by Shenzhen TV |
| |
●November , launch engineer reombinant antigen of TORCH Series(CMV, TOX,HSVII) |
| |
●December, develop HBV Monoclonal Antibody and firstly launch the core material of HCV (GICA Double-antigen Sandwiched) |
| |
●At the end of the year, the employee extented to 41 |
| |
|
| 2007 |
●Fabruary, start listing plan |
| |
●March, the company move to Nanyou 4th Industrial ,and launch the 1200m2 creative biotechnology R&D Lab |
| |
●April, construct the rapid diagnostic R&D platform |
| |
●July , attended AACC exhibition in San Diego |
| |
●August, Feipon Technology Co.,Ltd finished Joint-stock reform,which assets also increased to 1300 CNY, and renamed Fapon Biotech Inc. |
| |
●December, construct yeast expression platform |
| |
●December, successfully develop anti-PreS antibody for HBV |
| |
●At the end of the year, the employee extented to 36 |
| |
|
| 2006 |
●April, migrate to Ma Jia Long Industrial and the area expended to 450 m2 |
| |
●May ,aprroved as a high-tech enterprose in Shenzhen |
| |
●July, successfully launched projects of TORCH Seriess |
| |
●At the end of the year, our employee extented to 21 |
| |
|
| 2005 |
●April, the company area expended to 300 m2 |
| |
●July, He Zhiqiang and Hupeng、 Li Hongyan are respectively inaugurated as the president and vice president in Shenzhen Feipeng Technology CO., Ltd |
| |
●August, sucessfully develop HEV antigen for diagnostics. |
| |
●September, upgrade and replacement HIV recombinant angtigens and complete the development of HTLV recombinant antigens |
| |
●At the end of the year, the employee extented to 14 |
| |
|
| 2004 |
●June, Construct the R&D platform of monoclonal antibody. |
| |
●From june to august, Incumbent vice president(Hu Peng and Li hongyan) join in Feipeng Technology and complete the formation of the core enterpreneurial team |
| |
●December, successfully develop the first HCV recombinant antigen ELISA reagents( Double-antigen Sandwiched) |
| |
●At the end of the year, our employee extented to 10 |
| |
|
| 2003 |
●June , successfully develop TP recombinant antigen for IVD Research |
| |
●Ocotor, current president of He Zhiqiang joined in Shenzhen Feipeng Technology CO., Ltd |
| |
●December, successfully develop Rotavirus HCV recombinant antigen for IVD Research |
| |
●At the end of the year, our employee extented to 6 |
| |
|
| 2002 |
●August, successfully develop HIV recombinant antigen for IVD Research, and make the profit for the first time |
| |
●November, with 500,000 CNY registered capital, Fapon Technology Shenzhen Feipeng Technology CO., Ltd move to CIGNA Building, and the area expanded to 200m2 |
| |
●December, approved as a private technology enterprise in Shenzhen City |
| |
|
| 2001 |
●August 16, with 3 employee, 100.000 CNY registered capital and 15m2 area, Shenzhen Feipeng Technology CO.,Ltd founded in Liyuan Residential Quarter , Nanshan district, Shenzhen |
| |
●November, the company move to Tao Li garden, Nanshan district , Shenzhen |
History